Despite concerns over potential side effects, researchers seem more enthusiastic than ever about the prospect of treating Alzheimer’s with β-secretase inhibitors.
Sometimes challenged, the idea that pathogenic proteins spread through the brain got a lift from new animal model data presented at the frontotemporal dementia meeting.
Geneticists at frontotemporal dementia conference reported a new link with a ubiquitine enzyme and strengthened other gene associations.
Several such tests generated enthusiasm at the international frontotemporal dementia congress.
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
Researchers reported negative findings from three trials at ICFTD 2016.
With a laser focus on biomarkers and disease mechanisms, researchers at the 10th ICFTD meeting prepared the ground for therapeutic studies.
Read our full coverage of this year’s AAIC conference.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
Different genetic factors underlie amyloid accumulation and atrophy, researchers at AAIC reported.
Researchers at AAIC proposed several different measures of brain connectivity that may predict progression to AD.
Clinical trial design could benefit from new estimates of how slowly amyloid accumulates and how best to detect it at various disease stages.
BACE inhibitors are shaping up; pyroglutamate Aβ antibody clears plaques without ARIA, but immune reaction raises a flag.
Researchers at AAIC discussed technical limitations of current tracers and ways to improve the signal. A new ligand debuted that may be more specific for tangles.
Researchers at AAIC presented congruent data on the place tau tangles take in AD progression, and their close correlation with cognitive decline.